Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

ODAC Vote Aims to Introduce Clarity on Phase of Treatment Benefits in Resectable NSCLC

August 22nd 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail new trial design proposals for perioperative regimens in resectable NSCLC.

Dr Reckamp on Emerging EGFR TKIs in EGFR Exon 20 Insertion+ NSCLC

August 21st 2024

Karen L. Reckamp, MD, MS, discusses emerging EGFR TKIs in EGFR Exon 20–Mutated NSCLC.

Future Perioperative Trial Designs in NSCLC Need Adjustments Per FDA ODAC Consensus

August 20th 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, discuss data with perioperative durvalumab in resectable NSCLC in light of the ODAC decision.

FDA Grants BTD to GSK5764227 for Extensive-Stage Small Cell Lung Cancer

August 20th 2024

GSK5764227 has received breakthrough therapy designation from the FDA for use in select patients with extensive-stage small cell lung cancer.

Sacituzumab Tirumotecan NDA for EGFR+ NSCLC Under Review in China

August 20th 2024

An NDA seeking approval of sacituzumab tirumotecan for select patients with EGFR+ non–small cell lung cancer has been accepted by the NMPA's CDE.

FDA Approves First-Line Amivantamab Plus Lazertinib for EGFR+ Advanced NSCLC

August 20th 2024

The FDA has approved first-line amivantamab plus lazertinib for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

FDA Awards Orphan Drug Designation to PT217 for Neuroendocrine Carcinoma

August 19th 2024

The FDA has granted orphan drug designation to PT217 for the treatment of patients with neuroendocrine carcinoma.

FDA Lifts Partial Clinical Hold on Phase 1 Trial of YL202 in Advanced NSCLC and Breast Cancer

August 19th 2024

The FDA has lifted a partial clinical hold on the phase 1 trial evaluating YL202 in advanced breast cancer and EGFR-mutated non–small cell lung cancer.

Patient Selection and Sequencing of NSCLC ADCs

August 19th 2024

The panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.

Dr Stiles on the FDA Approval of Perioperative Durvalumab Plus Chemo in NSCLC

August 15th 2024

Brendon M. Stiles, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy in early-stage non–small cell lung cancer.

FDA Approves Perioperative Durvalumab Plus Chemotherapy in Resectable NSCLC

August 15th 2024

The FDA has approved neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab, for select resectable non–small cell lung cancer.

An Embarrassment of Riches in Oncology With Wayward Decision Support: A Recipe for Disaster?

August 15th 2024

Head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

Ivonescimab Under Priority Review by China’s NMPA for Frontline PD-L1–Positive NSCLC

August 15th 2024

Ivonescimab has been granted priority review in China for the frontline treatment of patients with PD-L1–positive locally advanced or metastatic NSCLC.

FDA Grants Priority Review to Durvalumab for LS-SCLC After Concurrent Chemoradiotherapy

August 15th 2024

The FDA granted priority review to durvalumab in limited-stage small cell lung cancer after platinum-based concurrent chemoradiotherapy.

Dr Oswalt on the Effects of Palliative Care Timing on End-of-Life Care in mNSCLC

August 15th 2024

Cameron James Oswalt MD, discusses a study evaluating the timing of palliative care referral and its effect on end-of-life care outcomes in mNSCLC.

Dr Raez on the FDA Approval of Repotrectinib in NTRK+ Solid Tumors

August 14th 2024

Luis E. Raez, MD, FACP, FCCP, discusses the significance of the FDA approval of repotrectinib in solid tumors harboring an NTRK gene fusion.

Deltacel Plus Radiation Wins FDA Fast Track Designation for Pretreated Metastatic NSCLC

August 14th 2024

The FDA has granted fast track designation to Deltacel in combination with low-dose radiation for pretreated metastatic non–small cell lung cancer.

Immune Therapy, EGFR Inhibition Take Hold of Stage III NSCLC

August 13th 2024

Clinicians specializing in caring for patients with lung cancer discussed clinical trial updates on agents in stage III NSCLC.

Dr Hirsch on the Benefits of Tissue vs Liquid Biopsy in NSCLC

August 12th 2024

Fred R. Hirsch, MD, PhD, discusses the pros and cons of completing a tissue biopsy compared with a liquid biopsy in non–small cell lung cancer.

Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd

August 12th 2024

Benjamin Levy, MD, compares the common toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd), and shares practical tips for managing these toxicities in the clinical setting to optimize patient care and minimize adverse effects.